Bispecific antibodies in multiple myeloma

The outcomes of multiple myeloma (MM) patients have significantly improved over recent years due to the introduction of novel therapies. Nevertheless, the disease remains incurable and the prognoses of patients with relapses are poor. T-cell redirecting bispecific antibodies (BsAbs) have recently demonstrated efficacy in patients with relapsed or refractory disease. Teclistamab, elranatamab, and talquetamab are novel BsAbs approved as monotherapies for the treatment of relapsed/refractory multiple myeloma (RRMM) refractory to proteasome inhibitors, immunomodulatory agents, and anti-CD38 antibodies. Their efficacy and safety have been demonstrated in phase II multicenter trials. Additionally, several other BsAbs are currently being investigated in clinical studies. Ongoing research is focused on expanding the application of BsAbs in MM, including their incorporation into earlier lines of treatment and their use in combination with other anti-myeloma agents. In this review, we discuss the tolerability and efficacy of three approved BsAbs i.e. teclistamab, elrantamab and talquetamab.